Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

GNPX vs CODX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CODX Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–3 Matrix Metrics)

CODX Overall Winner 6-Pillar Tally: GNPX 0 – 5 CODX (1 Tie) Matrix Metrics: GNPX 3 – 5 CODX

As of Nov 20, 2026, Co-Diagnostics, Inc. (CODX) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GNPX carries a Unified Composite Score of 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas CODX carries 42.7/100 (HOLD) at $0.13 (15.4x Forward P/E, -3415.8% operating margin).

  • Technical & Structure Timing Caution: GNPX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile CODX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GNPX vs CODX
GNPX NASDAQ
Genprex, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-13.17% 1D
Market Cap $2.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -4.68β · 96% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.2%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $2.00 · SMA50: $2.48
CODX NASDAQ Head-to-Head Winner
Co-Diagnostics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.13
-21.32% 1D
Market Cap $1.5M
TTM Revenue $858,888
Forward P/E 15.4x
Beta / 30D Vol 3.34β · 162% Vol
Unified Composite Score
42.7 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 66.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.6%), weak momentum, RSI 18
RSI-14: 17.8 · SMA20: $0.31 · SMA50: $0.70

6-Pillar Scorecard Institutional Category Breakdown (GNPX 0 – 5 CODX)

Columns: Metric · GNPX · CODX
1. Valuation Multiples CODX
Forward P/E N/M 15.4x
Trailing P/E N/M 15.4x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CODX
Revenue Growth (YoY) +0.0% +94.6%
Earnings Growth (YoY) +0.0% +30.8%
TTM Revenue (USD) N/A $858,888
Market Cap $2.2M $1.5M
3. Profitability & Quality CODX
Gross Margin N/A 20.3%
Operating Margin 0.0% -3415.8%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -233.7% -192.8%
4. Balance Sheet & Cash Flow CODX
Cash Generation (TTM) N/A -$28M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $11.26 Book/Sh · -233.7% ROE $6.2M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CODX
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 270.2% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GNPX (3) vs CODX (5)
Institutional Metric GNPX CODX Criterion Row Edge
Market Capitalization
Scale
$2.2M $1.5M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 15.4x Lower Multiple CODX
Forward P/E Ratio
Valuation
N/M 15.4x Lower Multiple CODX
Revenue Growth (YoY)
Growth
+0.0% +94.6% Higher Growth CODX
Operating Margin (TTM)
Profitability
0.0% -3415.8% Higher Margin GNPX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-233.7% -192.8% Higher ROE CODX
52-Week Range Position
Momentum
11% ($0–$10) 0% ($0–$14) Stronger Trend GNPX
Beta / 30D Volatility
Risk Regime
-4.68β · 96% Vol 3.34β · 162% Vol Lower Realized Risk GNPX
Unified Institutional Score
Composite Signal
42.2 / 100 (HOLD) 42.7 / 100 (HOLD) Higher Composite CODX
Trailing 12M Revenue (USD)
Operating Scale
N/A $858,888 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 20.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($11.26 Book/Sh · -233.7% ROE) -$28M EBITDA ($6.2M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GNPX +50.51 pp
GNPX: -26.77% · CODX: -77.28%
3M Horizon GNPX +25.46 pp
GNPX: -63.93% · CODX: -89.39%
6M Horizon GNPX +174.04 pp
GNPX: +76.59% · CODX: -97.45%
1Y Horizon GNPX +5.58 pp
GNPX: -56.59% · CODX: -62.17%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GNPX vs CODX. Trailing 12-month operating profitability (GNPX 0.0% vs CODX -3415.8%) and valuation multiples (GNPX N/M vs CODX 15.4x Forward P/E) are benchmarked directly in Pillar 4 below.

GNPX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-233.7% · N/M
CODX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$858,888
Gross Margin20.3%
Op. Margin-3415.8%
ROE / Fwd P/E-192.8% · 15.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GNPX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GNPX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CODX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 270.2%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CODX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GNPX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CODX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.5M market capitalization and -3415.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GNPX vs CODX Key Questions & Quantitative Answers

As of Nov 20, 2026, Co-Diagnostics, Inc. (CODX) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GNPX carries a Unified Composite Score of 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas CODX carries 42.7/100 (HOLD) at $0.13 (15.4x Forward P/E, -3415.8% operating margin). Technical & Structure Timing Caution: GNPX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile CODX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CODX leads the Growth & Scale pillar: GNPX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CODX at +94.6% YoY revenue growth and +30.8% YoY earnings growth on $858,888 TTM revenue (20.3% gross margin, -3415.8% operating margin). On trailing 12-month operating scale, GNPX generates N/A in USD-normalized revenue versus $858,888 for CODX. In operating R&D and SG&A reinvestment, GNPX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CODX.

CODX screens cheaper on headline valuation multiples. GNPX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CODX trades at 15.4x Forward P/E, 15.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GNPX (-233.7% ROE) versus CODX (-192.8% ROE) capital efficiency.

In options market volatility and institutional positioning, GNPX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.68β · 96% Vol realized risk). By comparison, CODX carries 270.2% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.34β · 162% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.